Efficacy of Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant Chronic Hepatitis C (CHC) Genotype 1 (GT 1) Subjects
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2006 |
| End Date: | September 2010 |
Assessment of the Efficacy of Pioglitazone on Viral Kinetics, Cytokines, and Innate Immunity in a Group of Insulin Resistant, Treatment Naïve, Chronic Hepatitis C, Genotype 1 Patients
The purpose of this study is to determine if rosiglitazone, a medicine used to treat
diabetes, improves response to anti-viral treatment.
The aim of the study will be to determine if an insulin sensitizing thiazolidinedione (TZD)
improves (1) baseline viremia, (2) enhances viral kinetics, (3) improves cytokine profiles
and (4) up regulates innate cellular immunity (presumably adaptive immunity is up regulated
as well) as measured by the bioactivity of the collected biomarkers.
We found this trial at
1
site
Click here to add this to my saved trials
